Quality of Life in Wilson’s Disease: A Systematic Literature Review

Autor: Chakrapani Balijepalli, Kevin Yan, Lakshmi Gullapalli, Stephane Barakat, Helene Chevrou-Severac, Eric Druyts

Publikováno v: Journal of Health Economics and Outcomes Research (2021)

**Background:** Wilson’s disease (WD) is a rare inherited genetic disorder characterized by the progressive accumulation of copper in the brain, liver, and other major organ systems. To date, there have been no comprehensive studies synthesizing ev

Externí odkaz: https://doaj.org/article/25d771255d974332aeae482bc75084ec

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting

Autor: Brian J. P. Huntly, Paula R Williamson, Kathryn L. Harrison, Katharina Lang, Tamás Bereczky, Renate Schulze-Rath, Lars Bullinger, Jan Geissler, Rory Goodbody, Jesús M. Hernández-Rivas, Helene Chevrou-Severac, Gert J. Ossenkoppele

Publikováno v: Lang, K M, Harrison, K L, Williamson, P R, Huntly, B J P, Ossenkoppele, G, Geissler, J, Bereczky, T, Hernández-Rivas, J M, Chevrou-Séverac, H, Goodbody, R, Schulze-Rath, R & Bullinger, L 2020, ' Core outcome set measurement for future clinical trials in acute myeloid leukemia : The HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting ', Trials, vol. 21, no. 1, 437 . https://doi.org/10.1186/s13063-020-04384-1
Trials, 21(1):437. BioMed Central
Trials, Vol 21, Iss 1, Pp 1-6 (2020)
Trials
Digital.CSIC. Repositorio Institucional del CSIC
instname

© The Author(s).
[Background]: Acute myeloid leukemia (AML) is the most common acute leukemia in adults and has an unacceptably low cure rate. In recent years, a number of new treatment strategies and compounds were developed for the treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d44e0855f14315cfe576bc663b2ee91
https://www.repository.cam.ac.uk/handle/1810/307595

A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models

Autor: Helene Chevrou-Severac, John Brazier, Roberta Ara, Donna Rowen

Publikováno v: PharmacoEconomics. 35:21-31

Generic preference-based measures (GPBMs) of health are used to obtain the quality adjustment weight required to calculate the quality-adjusted life year in health economic models. GPBMs have been developed to use across different interventions and m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae4a5926262131a2a87b3b14f709772
https://doi.org/10.1007/s40273-017-0545-x

Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

Autor: Lindsay Nicholson, Elizabeth M Adkins, Mark Ratcliffe, Helene Chevrou-Severac, David Floyd

Publikováno v: ClinicoEconomics and Outcomes Research: CEOR

Orphan drugs (ODs) are intended for the diagnosis, prevention, or treatment of rare diseases. Many cancer subtypes, including all childhood cancers, are defined as rare diseases, and over one-third of ODs are now intended to treat oncology indication

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2c4f86f0e961df503114c03db3d242
https://doi.org/10.2147/ceor.s134230

Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report

Autor: John Karnon, Roberta Ara, Luciane Nascimento Cruz, Helene Chevrou-Severac, Suzy Paisley, A. Simon Pickard, Andrew Lloyd, John Brazier, Bruce Crawford, Jan J. V. Busschbach, Ismail Azzabi

Publikováno v: Value in Health, 22(3), 267-275. Elsevier Ltd.

Cost-effectiveness models that present results in terms of cost per quality-adjusted life-year for health technologies are used to inform policy decisions in many parts of the world. Health state utilities (HSUs) are required to calculate the quality

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::807f1f79b3da9443a66b33ad95b37331
https://pure.eur.nl/en/publications/1087fca9-6cb0-460d-8230-abc5fe12df53